Yields and chondrogenic potential of primary synovial mesenchymal stem cells are comparable between rheumatoid arthritis and osteoarthritis patients

Table 1 Patient demographics

Group	Patient number	Age	Sex	CRP (mg/dl)	ESR (mm)	Medicine
						PSL (mg/day)	DMARDs other than biologics	Biologics
RA	#1	62	F	0.05	46		MTX	ADA
	#2	67	F	0.49	29		MTX
	#3	43	F	0.2	26	2	MTX
	#4	48	F	0.06	39
	#5	42	F	0.3	15	16	MTX	GLM
	#6	80	F	4.2	71		TCR, SASP, BUC
	#7	76	M	5.9	111		MTX
	#8	62	F	0.5	38
OA	#9	66	F	0.02	10
	#10	72	F	0.42	28
	#11	75	F	0.07	14
	#12	74	F	0.1	40
	#13	74	F	0.03	9
	#14	71	F	0.02	14
	#15	78	F	0.12	18
	#16	81	F	0.03	18

Male vs. female was 1:7 in the RA group and 0:8 in the OA group, showing no significant difference (p = 0.99 by Mann-Whitney’s U test). The mean of age was 60 years old in the RA group, and 74 years old in the OA group: no significant difference between them (p = 0.06 by Mann-Whitney’s U test)
CRP C-reactive protein, ESR erythrocyte sedimentation rate, PSL prednisolone, DMARDS disease-modifying antirheumatic drugs, MTX methotrexate, RA rheumatoid arthritis, ADA adalimumab, GLM golimumab, TCR tacrolimus,, SASP salazosulfapyridine, BUC bucillamine, OA osteoarthritis

ISSN: 1757-6512